Press Releases

May 16, 2018

Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
May 1, 2018

Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients

-- Agreement provides Praluent at lower net price and enables streamlined patient access based on physician attestation
Apr 30, 2018

FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 27, 2018

Sanofi: First-quarter 2018 Business EPS up 1.4% at CER
- Photos 5
Apr 25, 2018

FDA accepts for review Supplemental Biologics License Application for 0.5 mL dose of Fluzone® Quadrivalent (Influenza Vaccine) in children 6-35 months of age

- If approved, health care professionals will be able to use the same 0.5 mL dose of Fluzone Quadrivalent vaccine with all patients ages 6 months and older for whom flu vaccination is recommended - which may provide more flexibility and convenience to immunizers.

Show per page

Print
Email page
RSS